AVANTIC is proud to announce the expansion of its healthcare product portfolio with new additions across multiple therapeutic categories, reinforcing our commitment to accessible health solutions.
After years of rigorous research and clinical trials, Avantic Pharma's R&D division has officially announced the successful formulation of a next-generation compound targeting chronic hypertension. This breakthrough is set to redefine cardiovascular care by delivering unprecedented efficacy paired with an exceptional safety profile.
Cardiovascular diseases remain the leading cause of death worldwide. Recognizing the urgent need for more effective treatments, our scientific team embarked on an ambitious journey to isolate and synthesize a molecule that stabilizes blood pressure without the common side effects associated with current medications. Our new therapeutic approach not only addresses the immediate symptoms of hypertension but also works at the cellular level to promote vascular healing — a major step forward in extending patient lifespan and quality of life.
Clinical Trial Phase
During the Phase III double-blind, placebo-controlled clinical trials conducted across more than 40 medical centers in 12 countries, the compound consistently demonstrated a 40% improvement in sustained normal blood pressure compared to current market-leading treatments. Furthermore, the incidence of adverse effects dropped to less than 2%.
The new drug is expected to undergo final regulatory reviews by the FDA and the European Medicines Agency (EMA) next quarter. Avantic Pharma has already begun expanding its manufacturing capabilities to ensure a secure and rapid global supply chain once approvals are secured.
